These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 8141171

  • 1. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors.
    Schlueter W, Keilani T, Batlle DC.
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S81-6. PubMed ID: 8141171
    [Abstract] [Full Text] [Related]

  • 2. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Adrenal renin: a possible local regulator of aldosterone production.
    Mulrow PJ.
    Yale J Biol Med; 1989 Sep; 62(5):503-10. PubMed ID: 2697984
    [Abstract] [Full Text] [Related]

  • 5. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P.
    Praxis (Bern 1994); 1996 Feb 20; 85(8):227-33. PubMed ID: 8701189
    [Abstract] [Full Text] [Related]

  • 6. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 20; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 20; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. [The influence of ACE inhibitors on urinary electrolyte secretion and the response to transitory hypovolemia in chronic heart failure].
    Marenzi G, Lauri G, Assanelli E, Grazi M, Guazzi M, Berna G, Salvioni A, Agostoni P.
    Cardiologia; 1997 Dec 20; 42(12):1277-83. PubMed ID: 9534323
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 20; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 10. [Hyperkalemia during prolonged use of angiotensin II-converting enzyme inhibitors in end-stage renal insufficiency].
    Mooser V, Fellay G, Regamey C.
    Schweiz Med Wochenschr; 1992 Dec 12; 122(50):1927-9. PubMed ID: 1465596
    [Abstract] [Full Text] [Related]

  • 11. Reversal of the suppressed kidney renin level in the hypertensive transgenic rat TGR(mRen-2)27 by angiotensin converting enzyme inhibition.
    Tokita Y, Franco-Saenz R, Mulrow PJ.
    Am J Hypertens; 1995 Oct 12; 8(10 Pt 1):1031-9. PubMed ID: 8845072
    [Abstract] [Full Text] [Related]

  • 12. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC, Perazella MA.
    Am J Med; 2004 Feb 15; 116(4):263-72. PubMed ID: 14969655
    [Abstract] [Full Text] [Related]

  • 13. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Feb 15; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 14. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M, Brunner HR.
    Exp Nephrol; 1996 Feb 15; 4 Suppl 1():41-6. PubMed ID: 9001896
    [Abstract] [Full Text] [Related]

  • 15. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS, Weinberg AJ, Zappe DH.
    J Renin Angiotensin Aldosterone Syst; 2000 Sep 15; 1(3):217-33. PubMed ID: 11881029
    [No Abstract] [Full Text] [Related]

  • 16. Converting enzyme inhibitors normalize the reduced adrenal responsiveness to angiotensin II in essential hypertension.
    Williams GH, Hollenberg NK.
    J Hypertens Suppl; 1984 Dec 15; 2(2):S43-7. PubMed ID: 6100876
    [Abstract] [Full Text] [Related]

  • 17. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun 15; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 18. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
    Gensini GF, Lippi D, Conti AA.
    Recenti Prog Med; 2002 Oct 15; 93(10):544-53. PubMed ID: 12405014
    [Abstract] [Full Text] [Related]

  • 19. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 20. Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium.
    Keilani T, Schlueter W, Batlle D.
    J Clin Pharmacol; 1995 Jan 26; 35(1):87-97. PubMed ID: 7751417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.